| |
Thursday, December 7, 2023 | 2pm ET / 11am PT In this webinar, explore proven strategies, technology insights, and practical approaches to drive innovation, ensure data reproducibility, and unlock the potential of the Lab of the Future. Register now. 
|
|
Today’s Big NewsDec 1, 2023 |
|
Decemeber 5, 2023 | The Edison Ballroom, NYC A celebration of the 50 key players, changemakers and innovators across biotech, pharma and healthcare. The Fierce 50 is a groundbreaking project to identify, elevate and celebrate the individuals and companies driving advancements in medicine, fostering innovation and shaping the future of biopharma and healthcare. Register Now! 
|
|
| By Nick Paul Taylor Pfizer is continuing to pinball between oral obesity assets. Months after making twice-daily danuglipron its top prospect, the Big Pharma has dropped the program after more than half of people taking the drug candidate dropped out of a midphase clinical trial. |
|
|
|
By Fraiser Kansteiner AstraZeneca has put the kibosh on two late-stage Lokelma trials testing the hyperkalemia drug in patients with heart and kidney diseases. The studies were called off due to “substantially increased enrollment times and low event rates,” AZ said Friday. |
By Andrea Park The FDA is looking into a spate of quality complaints regarding plastic syringes manufactured in China. |
By Nick Paul Taylor Tiny Altimmune is slinging stones at the goliaths of the obesity market. Facing well set incumbents, the biotech pitched its midphase data as evidence that its GLP-1 candidate can carve out a niche in obesity patients at risk of cardiovascular events—but tolerability issues that marred an earlier data drop remain. |
By Angus Liu When it comes to expanding radiotherapy manufacturing capacity for Lutathera and Pluvicto, Novartis is putting its money where its mouth is. The Swiss pharma is investing about $85 million to build a new radiotherapy facility in China. |
By Andrea Park After developing a wearable device that can automatically detect seizures in people with epilepsy and immediately notify their caregivers, Empatica is planning to take the technology even further. |
By Gabrielle Masson Tang Capital Partners’ Concentra Biosciences is back with yet another biotech buyout offer, this time proposing to acquire LianBio in an all cash deal. |
By Zoey Becker The companies, which include Pfizer, J&J, Sanofi, AbbVie, AstraZeneca, Merck and others are being probed for potentially violating Turkish competition law, according to a release from the country's government. |
By Max Bayer FDA swiftly promotes Chief Scientist Bumpus to replace Woodcock. Amylyx names new CMO with post-approval clinical development in the spotlight. Spyre names Turtle CEO and adds host of new hires. |
By Fraiser Kansteiner As the battle between new respiratory syncytial virus vaccines heats up, GSK is “delighted” with the progress it's made so far with Arexvy, the company’s CEO Emma Walmsley said during a Reuters interview. Despite the vaccine's swift takeoff, there’s still “lots of headroom for growth," Walmsley added. |
Fierce podcasts Don’t miss an episode |
| In this episode of "The Top Line," we're highlighting the remarkable women featured in our annual Fiercest Women in Life Sciences special report. The list comprises 10 trailblazers changing the leadership landscape in pharma, biotech and medtech. |
|
|---|
|
|
|
Thursday, December 7, 2023 | 2pm ET / 11am PT Unlock the secrets to affordable autologous cell therapy manufacturing! Join our webinar to learn about cutting-edge solutions. Discover cost-effective closed-system designs for commercial scale production, bridging the gap between innovation and accessibility. Don't miss out on valuable insights into minimizing expenses in labor, equipment, materials, and facility footprint. Register now. 
|
|
Whitepaper Accelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
Whitepaper As a leader of technology transfer activities in the industry, Lonza understands the challenges associated with this critical step. Download this White Paper today to learn more. Sponsored by: Lonza |
eBook Emulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
Whitepaper A critical area to consider in selecting a CDMO is their ability to successfully complete technology transfers, which involves an intricate set of activities and disciplines that, if done incorrectly, could result in delays and failures that impact the overall success of your end product. Recognizing what it takes to complete this process effectively and efficiently is crucial to selecting the best partner for your project and product needs. This white paper delivers an analysis of critical success factors for effective technology transfer. Sponsored by: Lonza |
Whitepaper Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
Whitepaper Download our whitepaper to learn about plasmid DNA design considerations for cell and gene therapy applications. Sponsored by: Aldevron, a GMP manufacturing CDMO of DNA, RNA, and Proteins |
Whitepaper This paper explores AI’s potential impact on healthcare and on Medical Affairs (MA) more specifically. It also outlines what MA teams can do now to proactively leverage AI to improve service to their stakeholders. Presented by Blue Matter, strategic consultants in the life sciences |
| Edison Ballroom, New York City |
|
|
| |
|
